New obesity drug delivery compared in early trial
NCT ID NCT07226778
First seen Nov 10, 2025 · Last updated May 22, 2026 · Updated 22 times
Summary
This early-stage study compares how two different injection versions of the experimental drug maridebart cafraglutide are absorbed by the body. About 348 adults with overweight or obesity will receive a single dose of one version. The main goal is to measure drug levels in the blood and check for side effects.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for OBESITY are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
Anaheim Clinical Trials
Anaheim, California, 92801-2658, United States
-
Fortrea Clinical Research Unit - Dallas
Dallas, Texas, 75247-4989, United States
-
Fortrea Clinical Research Unit - Daytona Beach
Daytona Beach, Florida, 32117-5116, United States
-
Fortrea Clinical Research Unit Inc. - Madison
Madison, Wisconsin, 53704-2526, United States
Conditions
Explore the condition pages connected to this study.